EBITDA Margin (Quarterly)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

ARS Pharmaceuticals, Inc. (SPRY) EBITDA Margin data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$22.68M
Net Income	$-60.62M
Cost of Goods Sold	$6.29M
Gross Profit	$16.39M
Operating Expenses	$82.83M
Operating Income	$-60.15M
Non-Operating Income/Expense	$-0.47M
Pre-Tax Income	$-60.62M
Normalized Pre-Tax Income	$-60.62M
Income after Taxes	$-60.62M
Income from Continuous Operations	$-60.62M
Consolidated Net Income/Loss	$-60.62M
Normalized Income after Taxes	$-60.62M
EBIT	$-60.15M
EBITDA	$-60.74M
Weighted-Average Shares Outstanding (Basic)	99.30M
Weighted-Average Shares Outstanding (Diluted)	99.30M
Earnings per Share (EPS) (Basic)	$-0.61
Earnings per Share (EPS) (Diluted)	$-0.61
Balance Sheet Financials
Current Assets	$245.24M
Property, Plant, and Equipment	$2.29M
Long-Term Assets	$42.34M
Total Assets	$287.57M
Current Liabilities	$49.61M
Long-Term Debt	$171.19M
Long-Term Liabilities	$176.65M
Total Liabilities	$226.26M
Common Equity	$61.31M
Tangible Shareholders Equity	$47.13M
Shareholders Equity	$61.31M
Common Shares Outstanding	99.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-44.95M
Cash Flow from Investing Activities	$27.79M
Cash Flow from Financial Activities	$0.16M
Beginning Cash	$41.32M
End Cash	$24.32M
Increase/Decrease in Cash	$-17.00M
Stock-Based Compensation	$7.42M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.94
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.74
Debt to Equity Ratio	2.79
Gross Margin	72.29%
Operating Margin	-265.18%
EBIT Margin	-265.18%
EBITDA Margin	--
Pre-Tax Profit Margin	-267.26%
Profit Margin	-267.26%
Free Cash Flow	$-44.95M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.71
Receiveable Turnover	0.79
Days Sales in Receivables	113.73
Return on Equity	-98.87%
Return on Tangible Equity	-128.61%
Return on Assets	-21.08%
Return on Investments	-26.07%
Book Value Per Share	$0.62
Free Cash Flow per Share	$-0.45
Operating Cash Flow per Share	$-0.45

Data from Zacks Investment Research, Inc.